OKYO Pharma Future Growth

Future criteria checks 0/6

OKYO Pharma is forecast to grow earnings and revenue by 70.4% and 149.1% per annum respectively while EPS is expected to grow by 87.7% per annum.

Key information

70.4%

Earnings growth rate

87.7%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	149.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Feb 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:OK11 - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2025	13	6	4	4	1
3/31/2024	N/A	-7	-6	-6	1
3/31/2023	N/A	-7	-6	-6	1
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-5	-4	-4	N/A
3/31/2022	N/A	-4	-4	-4	N/A
12/31/2021	N/A	-4	-3	-3	N/A
9/30/2021	N/A	-4	-3	-3	N/A
6/30/2021	N/A	-3	-2	-2	N/A
3/31/2021	N/A	-3	-1	-1	N/A
12/31/2020	N/A	-1	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-1	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-4	-2	-2	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-4	-2	-2	N/A
12/31/2018	N/A	-3	N/A	N/A	N/A
9/30/2018	N/A	-2	-2	-2	N/A
6/30/2018	N/A	-11	-1	-1	N/A
3/31/2018	N/A	-20	-1	-1	N/A
12/31/2017	N/A	-20	-1	-1	N/A
9/30/2017	N/A	-19	-1	-1	N/A
6/30/2017	N/A	-10	-1	-1	N/A
3/31/2017	N/A	0	-1	-1	N/A
12/31/2016	N/A	0	0	0	N/A
9/30/2016	N/A	0	0	0	N/A
6/30/2016	N/A	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	0	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-4	N/A	-1	N/A
9/30/2014	N/A	-3	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A
12/31/2013	N/A	-8	N/A	-2	N/A
9/30/2013	N/A	-8	N/A	-2	N/A
6/30/2013	N/A	-5	N/A	-2	N/A
3/31/2013	N/A	-3	N/A	-3	N/A
12/31/2012	N/A	-3	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OK11 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OK11 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OK11 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OK11 is forecast to have no revenue next year.

High Growth Revenue: OK11 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OK11's Return on Equity is forecast to be high in 3 years time

OKYO Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies